The company is hoping that ACE1702 will validate its antibody cell conjugation technology and show that its proprietary NK cells are more effective than current cell-based therapies.
Based on the expression of S100A2 and S100A4 proteins, researchers predicted which patients were likely to experience poor outcomes and disease recurrence post-surgery.
The companies hope to combine their technologies to provide pharmaceutical customers with an end-to-end workflow for multiplex histological staining and imaging.
The data add to growing evidence supporting the use of HER2 therapy across solid tumors, though researchers find a difficult path to a tissue-agnostic approval.
